08:00 , Jan 17, 2005 |  BC Week In Review  |  Company News

Scancell, Merck KGaA deal

MRK's Biovation Ltd. subsidiary (Aberdeen, U.K.) will use its DeImmunisation technology on up to two additional antibodies from Scancell. The deal includes Scancell's SC101 antibody against Lewis y/b, a cell surface antigen that is overexpressed...
07:00 , Aug 30, 2004 |  BioCentury  |  Emerging Company Profile

Scancell Ltd.

Scancell Ltd. Nottingham, U.K. Technology: ImmunoBody to discover cancer vaccines Disease focus: Cancer Clinical status: Preclinical Founded: 1997 by Lindy Durrant, David Liu and Frank Carr Corporate partners: Celltech Group plc ; Genmab A/S ;...
08:00 , Jan 26, 2004 |  BC Week In Review  |  Company News

Eli Lilly, Merck KGaA deal

MRK subsidiary Biovation Ltd. (Aberdeen, U.K.) will apply its DeImmunisation technology to undisclosed biopharmaceuticals designed by LLY. Biovation will receive research revenues and is eligible for milestones and royalties if LLY elects to move forward...
07:00 , Jul 14, 2003 |  BC Week In Review  |  Company News

J&J, Merck KGaA deal

Biovation, a MRK company, will apply its DeImmunisation technology to undisclosed therapeutic proteins from JNJ subsidiary Centocor. DeImmunisation technology is designed to eliminate or reduce T cell responses. Biovation will receive research payments, and is...
07:00 , Jul 14, 2003 |  BioCentury  |  Tools & Techniques

Biovation's DeImmunization

Immunogenicity reduces efficacy of therapeutic proteins and has made it difficult to develop such molecules. Biovation Ltd. says its DeImmunization technology, which modifies T cell epitopes responsible for immunogenicity, can help solve this problem. Last...
07:00 , Jul 7, 2003 |  BC Extra  |  Company News

Biovation, Centocor protein deal

Biovation (Aberdeen, U.K.), a Merck KGaA (FSE:MRK) company, will apply its DeImmunisation technology to undisclosed therapeutic proteins from Centocor . DeImmunisation technology is designed to eliminate or reduce T cell responses. Biovation will receive research...
07:00 , May 26, 2003 |  BC Week In Review  |  Company News

Merck KGaA, Roche deal

MRK's Biovation Ltd. unit (Aberdeen, U.K.) will apply its DeImmunisation technology to undisclosed ROCZ targets. DeImmunisation technology is designed to eliminate or reduce T cell responses. Biovation will receive research payments, and is eligible for...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Company News

Biovation management update

Biovation Ltd. , Aberdeen, U.K.   Business: Proteomics, Antibodies   Promoted: Anita Hamilton to VP of therapeutic antibody discovery from senior research manager  ...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Company News

CXR management update

CXR Biosciences Ltd. , Dundee, U.K.   Business: ADMET   Hired: Fiona Adair as director of business development, formerly director of business development at Biovation Ltd.  ...
08:00 , Dec 16, 2002 |  BC Week In Review  |  Company News

Viventia Biotech Inc., Merck KGaA deal

MRK’s Biovation Ltd. unit (Aberdeen, U.K.) will apply its DeImmunisation technology to a cytotoxic VBI protein, for use in treating cancer. DeImmunisation technology is designed to eliminate or reduce T cell responses caused when a...